Friday, April 24, 2026
33 C
Bengaluru

Indian Pharma Regional Performance Analysis & Summary

Overall Market Performance (IPM)
• The Indian Pharmaceutical Market (IPM) recorded a total value of ₹229,260.6 crore, with an overall growth of 7.6% for Dec’24.
• Out of 26 regions, 12 states/regions grew faster than the IPM growth rate of 7.6%, while the rest grew equal to or slower.

Regional Zone-Wise Performance
1. North Zone (₹62,928.3 Cr, 27% MS, 8.0% Growth)
• Top Contributors: Uttar Pradesh (₹25,550.2 Cr, 41% MS), Delhi (₹10,756.3 Cr, 17% MS).
• Fastest Growing: Delhi (12.5%), Jammu & Kashmir (9.4%), Haryana (8.8%).
2. South Zone (₹60,758.9 Cr, 27% MS, 7.1% Growth)
• Top Contributors: Karnataka (₹13,486.8 Cr, 22% MS), Tamil Nadu (₹11,509.0 Cr, 19% MS).
• Fastest Growing: Chennai (11.6%), Telangana (8.9%), Tamil Nadu (8.2%).
3. East Zone (₹56,501.1 Cr, 25% MS, 7.4% Growth)
• Top Contributors: West Bengal (₹14,651.3 Cr, 26% MS), Bihar (₹12,078.9 Cr, 21% MS).
• Fastest Growing: Chhattisgarh (9.5%), Orissa (8.7%), Assam (7.6%).
4. West Zone (₹49,072.3 Cr, 21% MS, 8.0% Growth)
• Top Contributors: Maharashtra (₹19,780.5 Cr, 40% MS), Madhya Pradesh (₹10,154.7 Cr, 21% MS).
• Fastest Growing: Madhya Pradesh (9.8%), Maharashtra (8.6%), Gujarat (8.7%).

Key Highlights

✅ Fastest Growing State: Delhi (12.5%)
✅ Other High Growth Regions: Chennai (11.6%), Madhya Pradesh (9.8%)
✅ Largest Market Share Contributors: Uttar Pradesh (₹25,550.2 Cr, 41% MS), Maharashtra (₹19,780.5 Cr, 40% MS), and West Bengal (₹14,651.3 Cr, 26% MS).
✅ North and West Zones had the highest growth rate (8.0%), while the South Zone had the slowest (7.1%).

Conclusion
• Delhi, Chennai, and Madhya Pradesh were the fastest-growing states.
• North and West zones led in growth, while the South zone expanded relatively slower.
• Key markets like Uttar Pradesh, Maharashtra, and West Bengal dominate market share.
• Overall, 12 states/regions outpaced the IPM growth rate of 7.6%, showing strong market potential.

Data Source: IQVIA

Hot this week

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

Topics

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...
spot_img

Related Articles

spot_imgspot_img